Trial Profile
A phase Ib study of durvalumab (MEDI4736) tremelimumab combined with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms DEPARTURE
- 20 Jan 2024 Results assessing safety and efficacy of of durvalumab plus tremelimumab in combination with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion presented at the 2024 Gastrointestinal Cancers Symposium
- 04 Mar 2022 New trial record
- 22 Jan 2022 Trial design presented at the 2022 Gastrointestinal Cancers Symposium.